The suit argued that Axonics’ sacral neuromodulation systems, known as r-SNM, infringed US patents No. 8036756, No. 8626314, and No. 9463324, all of which pertain to the charging, temperature ...

Axonics commenced SNM commercial activities in Australia in March 2023. In May 2024, Axonics received regulatory approval from the TGA to market its F15 ® recharge-free SNM system.

Axonics, Inc. (AXNX) comes out victorious in a patent trial against Medtronic (MDT), as the jury rules in its favor, awarding Medtronic nothing.

Axonics, Inc. (Nasdaq: AXNX) today announced that the jury has returned a unanimous verdict in the patent infringement lawsuit brought by Medtronic ag ...

Unlike other SNM devices, Axonics’ r-SNM device also can be charged via wand extrinsically. “Some patients choose to charge it every Sunday night because that’s easier for them,” but the battery lasts ...

Axonics defeats Medtronic lawsuit in spine-stimulation patent trial By Blake Brittain September 19, 20247:31 AM PDTUpdated September 19, 2024 ...

Boston Scientific said on Thursday the U.S. Federal Trade Commission (FTC) has requested additional information from the medical device maker related to its $3.7 billion deal to buy Axonics .